Literature DB >> 26482610

Skp2 regulates non-small cell lung cancer cell growth by Meg3 and miR-3163.

Lin Su1, Dongrui Han2, Jingwen Wu3, Xueyun Huo4.   

Abstract

Maternally expressed gene 3 (Meg3) encodes a long non-coding RNA that has been shown to play a role in tumorigenesis. Skp2 is a component of the E3 ubiquitin ligase SCF that specifically promotes the ubiquitination-associated degradation of CDK inhibitor p27, and has been shown to promote cancer cell growth in different types of cancers, including non-small cell lung cancer (NSCLC). Nevertheless, a regulatory relationship between Meg3 and Skp2 has not been acknowledged. Here, we showed that NSCLC specimens had significant higher levels of Skp2 and significantly lower levels of Meg3, compared to paired non-tumor lung tissue. The levels of Meg3 and Skp2 were inversely correlated in NSCLC specimens. Patients with low Meg3 levels had a poor survival. Overexpression of Meg3 decreased Skp2 protein and increased p27 protein, while depletion of Meg3 increased Skp2 protein and decreased p27 protein in NSCLC cells, without altering Skp2 mRNA. These data suggest that the Skp2 may be regulated by Meg3 at post-transcriptional level. Bioinformatics analyses showed that miR-3163 bound to 3'-UTR of Skp2 mRNA in NSCLC cells to inhibit its translation, which was supported by luciferase reporter assay. Meg3 augmented the effects of miR-3163 on Skp2 mRNA, possibly through binding-induced function enhancement, which was supported by the double fluorescent in situ hybridization showing co-localized intracellular Meg3 and miR-3163 signals in NSCLC cells. The miR-3163 levels in NSCLC were not different from in NT, suggesting that the regulation of Skp2 in NSCLC by miR-3163 may require coordination of Meg3. Thus, our data suggest that Meg3 and miR-3163 may coordinate suppression of translation of Skp2 mRNA in NSCLC cells to inhibit NSCLC cell growth.

Entities:  

Keywords:  Maternally expressed gene 3 (Meg3); Non-small cell lung cancer (NSCLC); Skp2; miR-3163

Mesh:

Substances:

Year:  2015        PMID: 26482610     DOI: 10.1007/s13277-015-4151-2

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  32 in total

1.  Structural basis of the Cks1-dependent recognition of p27(Kip1) by the SCF(Skp2) ubiquitin ligase.

Authors:  Bing Hao; Ning Zheng; Brenda A Schulman; Geng Wu; Julie J Miller; Michele Pagano; Nikola P Pavletich
Journal:  Mol Cell       Date:  2005-10-07       Impact factor: 17.970

2.  Regulation of growth of human bladder cancer by miR-192.

Authors:  Yongchao Jin; Jiasun Lu; Jiling Wen; Yinzhou Shen; Xiaofei Wen
Journal:  Tumour Biol       Date:  2015-01-09

3.  MiRNA-181c inhibits EGFR-signaling-dependent MMP9 activation via suppressing Akt phosphorylation in glioblastoma.

Authors:  Fei Wang; Weizhong Xiao; Jiyong Sun; Donghua Han; Youhou Zhu
Journal:  Tumour Biol       Date:  2014-05-28

4.  MiRNA-34a inhibits EGFR-signaling-dependent MMP7 activation in gastric cancer.

Authors:  Gang Liu; Chuanshen Jiang; Dazhou Li; Rong Wang; Wen Wang
Journal:  Tumour Biol       Date:  2014-07-01

5.  Skp2 overexpression increases the expression of MMP-2 and MMP-9 and invasion of lung cancer cells.

Authors:  Wen-Chun Hung; Wei-Lung Tseng; Jentaie Shiea; Hui-Chiu Chang
Journal:  Cancer Lett       Date:  2009-07-21       Impact factor: 8.679

6.  STAT3 interacts with Skp2/p27/p21 pathway to regulate the motility and invasion of gastric cancer cells.

Authors:  Zheng Wei; Xian Jiang; Haiquan Qiao; Bo Zhai; Lianfeng Zhang; Qiang Zhang; Yuanhong Wu; Hongchi Jiang; Xueying Sun
Journal:  Cell Signal       Date:  2013-01-17       Impact factor: 4.315

7.  Amplification and overexpression of SKP2 are associated with metastasis of non-small-cell lung cancers to lymph nodes.

Authors:  Sana Yokoi; Kohichiroh Yasui; Miki Mori; Toshihiko Iizasa; Takehiko Fujisawa; Johji Inazawa
Journal:  Am J Pathol       Date:  2004-07       Impact factor: 4.307

8.  Skp2 gene copy number aberrations are common in non-small cell lung carcinoma, and its overexpression in tumors with ras mutation is a poor prognostic marker.

Authors:  Chang Qi Zhu; Fiona H Blackhall; Melania Pintilie; Pratibha Iyengar; Ni Liu; James Ho; Taylor Chomiak; Davina Lau; Timothy Winton; Frances A Shepherd; Ming-Sound Tsao
Journal:  Clin Cancer Res       Date:  2004-03-15       Impact factor: 12.531

9.  The Diagnostic and Prognostic Role of microRNA in Colorectal Cancer - a Comprehensive review.

Authors:  Haggi Mazeh; Ido Mizrahi; Nadia Ilyayev; David Halle; Bjoern Brücher; Anton Bilchik; Mladjan Protic; Martin Daumer; Alexander Stojadinovic; Avital Itzhak; Aviram Nissan
Journal:  J Cancer       Date:  2013-03-20       Impact factor: 4.207

10.  Busulfan inhibits growth of human osteosarcoma through miR-200 family microRNAs in vitro and in vivo.

Authors:  Qiang Mei; Fang Li; Hongyu Quan; Yunlai Liu; Haidong Xu
Journal:  Cancer Sci       Date:  2014-07-03       Impact factor: 6.716

View more
  21 in total

1.  LncRNA OIP5-AS1 promotes cell proliferation and migration and induces angiogenesis via regulating miR-3163/VEGFA in hepatocellular carcinoma.

Authors:  Changsheng Shi; Qing Yang; Songsong Pan; Xingcheng Lin; Gending Xu; Ya Luo; Bingru Zheng; Xiangpang Xie; Mingxu Yu
Journal:  Cancer Biol Ther       Date:  2020-04-24       Impact factor: 4.742

2.  MicroRNAs association with azoospermia, oligospermia, asthenozoospermia, and teratozoospermia: a systematic review.

Authors:  Yousef Daneshmandpour; Zahra Bahmanpour; Hamid Hamzeiy; Marziyeh Mazaheri Moghaddam; Madiheh Mazaheri Moghaddam; Bahareh Khademi; Ebrahim Sakhinia
Journal:  J Assist Reprod Genet       Date:  2020-03-18       Impact factor: 3.412

3.  CRISPR/Cas9 uPAR Gene Knockout Results in Tumor Growth Inhibition, EGFR Downregulation and Induction of Stemness Markers in Melanoma and Colon Carcinoma Cell Lines.

Authors:  Alessio Biagioni; Anastasia Chillà; Mario Del Rosso; Gabriella Fibbi; Francesca Scavone; Elena Andreucci; Silvia Peppicelli; Francesca Bianchini; Lido Calorini; Anna Li Santi; Pia Ragno; Francesca Margheri; Anna Laurenzana
Journal:  Front Oncol       Date:  2021-05-14       Impact factor: 6.244

4.  Unveiling massive numbers of cancer-related urinary-microRNA candidates via nanowires.

Authors:  Takao Yasui; Takeshi Yanagida; Satoru Ito; Yuki Konakade; Daiki Takeshita; Tsuyoshi Naganawa; Kazuki Nagashima; Taisuke Shimada; Noritada Kaji; Yuta Nakamura; Ivan Adiyasa Thiodorus; Yong He; Sakon Rahong; Masaki Kanai; Hiroshi Yukawa; Takahiro Ochiya; Tomoji Kawai; Yoshinobu Baba
Journal:  Sci Adv       Date:  2017-12-15       Impact factor: 14.136

5.  Upregulation of the lncRNA Meg3 induces autophagy to inhibit tumorigenesis and progression of epithelial ovarian carcinoma by regulating activity of ATG3.

Authors:  Yin-Ling Xiu; Kai-Xuan Sun; Xi Chen; Shuo Chen; Yang Zhao; Qing-Guo Guo; Zhi-Hong Zong
Journal:  Oncotarget       Date:  2017-05-09

Review 6.  Emerging Roles of SKP2 in Cancer Drug Resistance.

Authors:  Ting Wu; Xinsheng Gu; Hongmei Cui
Journal:  Cells       Date:  2021-05-10       Impact factor: 6.600

7.  The expression of miR-513c and miR-3163 was downregulated in tumor tissues compared with normal adjacent tissue of patients with breast cancer.

Authors:  Soheila Delgir; Khandan Ilkhani; Asma Safi; Yazdan Rahmati; Vahid Montazari; Zahra Zaynali-Khasraghi; Farhad Seif; Milad Bastami; Mohammad Reza Alivand
Journal:  BMC Med Genomics       Date:  2021-07-07       Impact factor: 3.063

8.  MiR-506 exerts antineoplastic effects on osteosarcoma cells via inhibition of the Skp2 oncoprotein.

Authors:  Lu Ding; Rongxin Sun; Qi Yan; Chengwei Wang; Xiaoping Han; Yong Cui; Rong Li; Jiwen Liu
Journal:  Aging (Albany NY)       Date:  2021-02-17       Impact factor: 5.682

9.  RIG-I inhibits pancreatic β cell proliferation through competitive binding of activated Src.

Authors:  Yi Pan; GuangMing Li; HengGao Zhong; MeiJuan Chen; TingTing Chen; LiLi Gao; HuiWen Wu; Jun Guo
Journal:  Sci Rep       Date:  2016-06-28       Impact factor: 4.379

Review 10.  Intersecting transcriptomic profiling technologies and long non-coding RNA function in lung adenocarcinoma: discovery, mechanisms, and therapeutic applications.

Authors:  Jonathan Castillo; Theresa R Stueve; Crystal N Marconett
Journal:  Oncotarget       Date:  2017-06-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.